Article
Multidisciplinary Sciences
Silvia Chiesa, Antonella Mangraviti, Maurizio Martini, Tonia Cenci, Ciro Mazzarella, Simona Gaudino, Serena Bracci, Antonella Martino, Giuseppe M. Della Pepa, Martina Offi, Marco Gessi, Rosellina Russo, Matia Martucci, Francesco Beghella Bartoli, Luigi M. Larocca, Liverana Lauretti, Alessandro Olivi, Roberto Pallini, Mario Balducci, Quintino Giorgio D'Alessandris
Summary: This study aimed to identify molecular predictive factors for response to regorafenib in recurrent IDH-wildtype glioblastoma patients and found that mutations in the MAPK pathway may predict poor response and shorter survival in patients treated with regorafenib.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Jonathan P. S. Knisely, Howard A. Fine
Summary: The Oncology Grand Rounds series aims to provide clinical context to original reports published in the Journal. It includes case presentations, discussions on diagnostic and management challenges, literature reviews, and suggested management approaches by the authors. The goal is to help readers apply key study findings, including those from the Journal of Clinical Oncology, to their own clinical practice.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Martin Glas, Matthew T. Ballo, Ze'ev Bomzon, Noa Urman, Shay Levi, Gitit Lavy-Shahaf, Suriya Jeyapalan, Terence T. Sio, Paul M. DeRose, Martin Misch, Sophie Taillibert, Zvi Ram, Andreas F. Hottinger, Jacob Easaw, Chae-Yong Kim, Suyash Mohan, Roger Stupp
Summary: TTFields treatment affects the rate of distant progression in newly diagnosed GBM patients, with distant lesions appearing further from the primary lesion in the TTFields treatment arm. Distant progression correlates with improved clinical outcomes in TTFields patients.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Cell Biology
Inge Compter, Danielle B. P. Eekers, Ann Hoeben, Kasper M. A. Rouschop, Bart Reymen, Linda Ackermans, Jan Beckervordersantforth, Noel J. C. Bauer, Monique M. Anten, Pieter Wesseling, Alida A. Postma, Dirk De Ruysscher, Philippe Lambin
Summary: Treatment with chloroquine in combination with radiotherapy and concurrent temozolomide for newly diagnosed glioblastoma showed favorable toxicity and promising overall survival. The maximum tolerated dose was determined to be 200 mg of chloroquine daily. Further clinical studies are supported by these results.
Article
Cell Biology
Wenpeng Zhao, Liang Zhang, Yaya Zhang, Zhengye Jiang, Hanwen Lu, Yuanyuan Xie, Wanhong Han, Wentao Zhao, Jiawei He, Zhongjie Shi, Huiying Yang, Junjie Chen, Sifang Chen, Zhangyu Li, Jianyao Mao, Liwei Zhou, Xin Gao, Wenhua Li, Guowei Tan, Bingchang Zhang, Zhanxiang Wang
Summary: AT7519, a second-generation small molecule multi-CDK inhibitor, was found to have potential for GBM treatment through high-throughput screening. It inhibits cell viability and proliferation of GBM cells, arrests the cell cycle, induces apoptosis and pyroptosis, and reduces tumor volume in animal models. AT7519 is a promising chemical for GBM treatment.
CELL DEATH & DISEASE
(2023)
Editorial Material
Biochemistry & Molecular Biology
Kirit Singh, Kelly M. Hotchkiss, Ian F. Parney, John De Groot, Solmaz Sahebjam, Nader Sanai, Michael Platten, Evanthia Galanis, Michael Lim, Patrick Y. Wen, Giuseppe Minniti, Howard Colman, Timothy F. Cloughesy, Minesh P. Mehta, Marjolein Geurts, Isabel Arrillaga-Romany, Annick Desjardins, Kirk Tanner, Susan Short, David Arons, Elizabeth Duke, Wolfgang Wick, Stephen J. Bagley, David M. Ashley, Priya Kumthekar, Roel Verhaak, Anthony J. Chalmers, Anoop P. Patel, Colin Watts, Peter E. Fecci, Tracy T. Batchelor, Michael Weller, Michael A. Vogelbaum, Matthias Preusser, Mitchel S. Berger, Mustafa Khasraw
Summary: A breakthrough in drug discovery for glioblastoma necessitates the consecutive collection of central nervous system tissue through window of opportunity trials.
Article
Oncology
Cameron Czech, Ashley Chen, Katherine P. Morgan, Carlos Zamora, Sherif El-Refai, Norleena Poynter, Simon Khagi
Summary: This report presents a case of a patient with isocitrate dehydrogenase wild-type GBM and underlying RET amplification, who achieved a significant response to therapy with the RET inhibitor selpercatinib. The case highlights the excellent blood-brain barrier penetration of selpercatinib and its potential role in managing RET-amplified GBM.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Pharmacology & Pharmacy
Jigang Chen, Xin Tong, Mingyang Han, Songfeng Zhao, Linjin Ji, Yongkai Qin, Zilong He, Yuesong Pan, Chunhui Wang, Aihua Liu
Summary: The study found that RT plus TMZ treatment for elderly GBM patients in the US is associated with higher costs, but offers greater long-term survival and quality of life benefits. However, in China, this treatment strategy is not cost-effective and requires a decrease in the price of TMZ.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Sang-Soo Choi, Haeyoun Choi, In-Cheol Baek, Soon A. Park, Jae-Sung Park, Tai-Gyu Kim, Sin-Soo Jeun, Stephen Ahn
Summary: This case-control study evaluated the association between HLA polymorphism and the risk of glioblastoma development in Koreans. Findings suggest that certain HLA types may affect the development of glioblastoma in Koreans. Further research with larger sample sizes is needed to confirm the role of HLA polymorphisms in the pathogenesis of glioblastoma.
Review
Oncology
Raj Singh, Eric J. Lehrer, Ming Wang, Haley K. Perlow, Nicholas G. Zaorsky, Daniel M. Trifiletti, Joseph Bovi, Pierina Navarria, Silvia Scoccianti, Vinai Gondi, Paul D. Brown, Joshua D. Palmer
Summary: DE-RT alone showed superior PFS and OS compared to SoC-RT alone in patients with glioblastoma multiforme. However, DE-RT + TMZ did not lead to improved outcomes compared to SoC-RT + TMZ, and no differential benefit based on MGMT status was found. Future studies are needed to identify which subgroups benefit most from DE-RT.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Multidisciplinary Sciences
Andrew J. Brenner, John Floyd, Lisa Fichtel, Joel Michalek, Kunal P. Kanakia, Shiliang Huang, David Reardon, Patrick Y. Wen, Eudocia Quant Lee
Summary: The study investigated the safety and efficacy of Evo in combination with bevacizumab for treating bevacizumab refractory glioblastoma patients. Results showed a median overall survival of approximately 4.6 months with a median time to disease progression of 53 days from best response. The progression free survival at 4 months (PFS-4) on Evo-Bev treatment demonstrated a statistically significant improvement.
SCIENTIFIC REPORTS
(2021)
Article
Cell Biology
Dylan Jones, Clarissa A. Whitehead, Marija Dinevska, Samuel S. Widodo, Liam M. Furst, Andrew P. Morokoff, Andrew H. Kaye, Katharine J. Drummond, Theo Mantamadiotis, Stanley S. Stylli
Summary: Glioblastoma is a highly invasive and destructive brain tumor, and current standard treatments often fail to effectively eliminate it. In this study, we investigate the effects of several FDA-approved drugs on the invasion and viability of GBM cells. We found that these drugs can reduce cell invasion and viability, suggesting their potential as therapeutic options for GBM.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2023)
Article
Oncology
Hong Shik Yun, Jennifer Lee, Whoon Jong Kil, Tamalee R. Kramp, Philip J. Tofilon, Kevin Camphausen
Summary: AZD0530, a potent small-molecule inhibitor of the Src kinase family, enhances the radiosensitivity of glioblastoma cells and glioblastoma stem-like cells, showing potential as a clinical radiosensitizer for the treatment of glioblastoma.
MOLECULAR CANCER THERAPEUTICS
(2021)
Article
Oncology
J. Biau, E. Thivat, E. Chautard, D. Stefan, M. Boone, B. Chauffert, C. Bourgne, D. Richard, I Molnar, S. Levesque, R. Bellini, F. Kwiatkowski, L. Karayan-Tapon, P. Verrelle, C. Godfraind, X. Durando
Summary: This phase 1 trial aimed to determine the maximum tolerated dose of a p38-MAPK inhibitor, ralimetinib, in combination with radiotherapy and chemotherapy for newly diagnosed GBM patients. The study found that the MTD of ralimetinib was 100 mg/12 h, with the main dose-limiting toxicities being hepatic cytolysis and rash.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
James H. Park, Abdullah H. Feroze, Samuel N. Emerson, Anca B. Mihalas, C. Dirk Keene, Patrick J. Cimino, Adrian Lopez Garcia de Lomana, Kavya Kannan, Wei-Ju Wu, Serdar Turkarslan, Nitin S. Baliga, Anoop P. Patel
Summary: In this study, the authors modeled the tumor evolutionary trajectories during standard-of-care treatment for glioblastoma using multi-omic single-cell analysis. They identified a network of regulators that mediate treatment-induced shifts in tumor cell states and developed consensus networks that modulate cell state transitions across primary and recurrent tumor cells. By matching targeted therapies to active regulatory networks, they proposed a framework for applying single-cell-based precision medicine approaches to individual patients in different treatment settings.
NPJ PRECISION ONCOLOGY
(2022)
Article
Clinical Neurology
Nityanand Miskin, Prashin Unadkat, Michael E. Carlton, Alexandra J. Golby, Geoffrey S. Young, Raymond Y. Huang
Article
Clinical Neurology
W. Han, L. Qin, C. Bay, X. Chen, K. -H. Yu, N. Miskin, A. Li, X. Xu, G. Young
AMERICAN JOURNAL OF NEURORADIOLOGY
(2020)
Article
Computer Science, Interdisciplinary Applications
Min Zhang, Chen Zhang, Xian Wu, Xinhua Cao, Geoffrey S. Young, Huai Chen, Xiaoyin Xu
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
(2020)
Article
Clinical Neurology
Bo Hou, Lu Gao, Lin Shi, Yishan Luo, Xiaopeng Guo, Geoffrey S. Young, Lei Qin, Huijuan Zhu, Lin Lu, Zihao Wang, Ming Feng, Xinjie Bao, Renzhi Wang, Bing Xing, Feng Feng
Summary: The study reveals widespread brain volume loss in active Cushing's disease patients, but significant improvement after TSS. Most brain regions in remitted CD patients showed full recovery, except for the frontal and temporal lobes. ACTH and serum cortisol changes were negatively correlated with brain volume recovery.
JOURNAL OF NEUROSURGERY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Min Zhang, Geoffrey S. Young, Huai Chen, Jing Li, Lei Qin, J. Ricardo McFaline-Figueroa, David A. Reardon, Xinhua Cao, Xian Wu, Xiaoyin Xu
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2020)
Article
Clinical Neurology
Ellen J. Bubrick, Taha Gholipour, Matthew Hibert, G. Rees Cosgrove, Steven M. Stufflebeam, Geoffrey S. Young
Summary: This study investigated the added value of 7T MRI in presurgical evaluation of drug-resistant focal epilepsy patients. The results showed that 7T MRI can detect new lesions in patients without lesions on 3T MRI, confirm and better characterize suspected lesions on 3T MRI, and help exclude suspected lesions on 3T MRI. The initial experience suggests that 7T MRI improves the detection and characterization of suspected brain lesions in these patients, adding value to surgical planning.
JOURNAL OF NEUROIMAGING
(2022)
Correction
Neurosciences
Alain Ndayisaba, Ariana T. Pitaro, Andrew S. Willett, Kristie A. Jones, Claudio Melo de Gusmao, Abby L. Olsen, Jisoo Kim, Eero Rissanen, Jared K. Woods, Sharan R. Srinivasan, Anna Nagy, Amanda Nagy, Merlyne Mesidor, Steven Cicero, Viharkumar Patel, Derek H. Oakley, Idil Tuncali, Katherine Taglieri-Noble, Emily C. Clark, Jordan Paulson, Richard C. Krolewski, Gary P. Ho, Albert Y. Hung, Anne-Marie Wills, Michael T. Hayes, Jason P. Macmore, Luigi Warren, Pamela G. Bower, Carol B. Langer, Lawrence R. Kellerman, Christopher W. Humphreys, Bonnie I. Glanz, Elodi J. Dielubanza, Matthew P. Frosch, Roy L. Freeman, Christopher H. Gibbons, Nadia Stefanova, Tanuja Chitnis, Howard L. Weiner, Clemens R. Scherzer, Sonja W. Scholz, Dana Vuzman, Laura M. Cox, Gregor Wenning, Jeremy D. Schmahmann, Anoopum S. Gupta, Peter Novak, Geoffrey S. Young, Mel B. Feany, Tarun Singhal, Vikram Khurana
Article
Neurosciences
Alain Ndayisaba, Ariana T. Pitaro, Andrew S. Willett, Kristie A. Jones, Claudio Melo de Gusmao, Abby L. Olsen, Jisoo Kim, Eero Rissanen, Jared K. Woods, Sharan R. Srinivasan, Anna Nagy, Amanda Nagy, Merlyne Mesidor, Steven Cicero, Viharkumar Patel, Derek H. Oakley, Idil Tuncali, Katherine Taglieri-Noble, Emily C. Clark, Jordan Paulson, Richard C. Krolewski, Gary P. Ho, Albert Y. Hung, Anne-Marie Wills, Michael T. Hayes, Jason P. Macmore, Luigi Warren, Pamela G. Bower, Carol B. Langer, Lawrence R. Kellerman, Christopher W. Humphreys, Bonnie I. Glanz, Elodi J. Dielubanza, Matthew P. Frosch, Roy L. Freeman, Christopher H. Gibbons, Nadia Stefanova, Tanuja Chitnis, Howard L. Weiner, Clemens R. Scherzer, Sonja W. Scholz, Dana Vuzman, Laura M. Cox, Gregor Wenning, Jeremy D. Schmahmann, Peter Novak, Geoffrey S. Young, Mel B. Feany, Tarun Singhal, Vikram Khurana
Summary: The article introduces the process of developing a clinical trial-ready cohort of patients with Multiple System Atrophy (MSA) in an outpatient clinical setting, and the use of different tests and data collection methods to better understand disease progression and patient characteristics. Additionally, using induced pluripotent stem cell (iPSC) models from patient samples can provide more accurate information and help match patients with appropriate treatments.
Article
Neurosciences
Jisoo Kim, Geoffrey S. Young, Andrew S. Willett, Ariana T. Pitaro, Grace F. Crotty, Merlyne Mesidor, Kristie A. Jones, Camden Bay, Min Zhang, Mel B. Feany, Xiaoyin Xu, Lei Qin, Vikram Khurana
Summary: Using automated decision-tree analysis with MRI data, it is possible to differentiate different neurodegenerative movement disorders and their relation to multiple system atrophy with promising accuracy and potential for clinical translation.
Proceedings Paper
Engineering, Biomedical
Wei Han, Lei Qin, Camden Bay, Xin Chen, Kun-Hsing Yu, Angie Li, Xiaoyin Xu, Geoffrey S. Young
Summary: In this study, deep learning models and an elastic net-Cox model were used to distinguish GBM patients into survival groups, with the combined feature framework showing predictive value for OS in both datasets with a log-rank test p-value < 0.05. This suggests the potential for further study on reproducible prediction of treatment response.
MEDICAL IMAGING 2020: IMAGE PROCESSING
(2021)
Proceedings Paper
Engineering, Biomedical
Min Zhang, Dongsheng An, Geoffrey S. Young, Xianfeng Gu, Xiaoyin Xu
Summary: This work introduces a novel differential geometry-based quasi conformal (QC) mapping augmentation technique to enhance brain tumor images in the medical imaging field. By solving the Beltrami equation with given Beltrami coefficient, the QC map is able to generate all possible linear and non-linear image warpings, with flexibility in controlling global and local deformations. Experimental results demonstrate the efficiency and efficacy of the proposed method.
MEDICAL IMAGING 2020: IMAGE PROCESSING
(2021)
Meeting Abstract
Oncology
Bryan Iorgulescu, Mary Jane Lim-Fat, Lei Qin, Gareth Grant, Raymond Huang, Geoffrey Young, David Reardon
Meeting Abstract
Oncology
Benjamin M. Ellingson, Raymond Yi-kun Huang, Javier Villanueva-Meyer, Mary Jane Lim-Fat, Elizabeth George, Bryan Iorgulescu, Geoffrey Young, Catalina Raymond, Talia Oughourlian, Jacob Schlossman, Tyler Gleason, Nancy Ann Oberheim Bush, Patrick Y. Wen, Timothy Francis Cloughesy, Susan Marina Chang, David A. Reardon, Michael Weller, Hideho Okada
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Computer Science, Software Engineering
Aditeya Pandey, Harsh Shukla, Geoffrey S. Young, Lei Qin, Amir A. Zamani, Liangge Hsu, Raymond Huang, Cody Dunne, Michelle A. Borkin
IEEE TRANSACTIONS ON VISUALIZATION AND COMPUTER GRAPHICS
(2020)
Meeting Abstract
Clinical Neurology
Isaac Solomon, Hirotaka Ito, Hiroshi Nakashima, Yu Zeng, Kristine Pelton, Fiona Watkinson, Kin-Hoe Chow, Nathan Matthewson, Geoffrey Young, David Reardon, Scott Rodig, Sandro Santagata, Mario Suva, Kai Wucherpfennig, Sean Lawler, E. Chiocca, Keith Ligon
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
(2019)